瑞康醫藥(002589.SZ):2023年度預盈2000萬元–3000萬元
格隆匯1月30日丨瑞康醫藥(002589.SZ)公佈2023年度業績預吿,報吿期歸屬於上市公司股東的淨利潤盈利2,000萬元–3,000萬元,同比扭虧為盈;扣除非經常性損益後的淨利潤虧損13,000萬元–19,000萬元,比上年同期減少虧損79.52%-85.98%;基本每股收益盈利0.0133元/股–0.0199元/股。
2023年業績較上年同期扭虧為盈的主要原因:處置子公司影響投資收益、公允價值變動收益,公司與前期部分失控出表的子公司達成和解,由控股子公司的少數股東回購股權。同時,公司處置部分與主營業務不相關的子公司。上述情況處置子公司對上市公司的投資收益、公允價值變動收益影響預計約為2億元,此部分被認定為非經常性損益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.